Consistent with recent studies of PD-(L)1 monotherapy in metastatic setting, we found that very high PD-L1 expression, namely PD-L1 TPS ≥ 90%, associates with favorable treatment outcomes in patients with stage III NSCLC treated with CRT and durvalumab consolidation. This evidence concerns the gene CD274 and non-small cell lung carcinoma.